About 3 results found for searched term "MGCD265" (0.128 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1922 | MGCD265 | c-Met |
| MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal epithelial transition (c-Met) and the vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3). | ||
| M14918 | Glesatinib hydrochloride | Others |
| MGCD265 hydrochloride | ||
| Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. | ||
| M30936 | Glesatinib | TAM Receptor |
| MGCD265 | ||
| Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
